B Ribba

Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development

J Chard, R Kaye, S Moodie, 2015, CPT: pharmacometrics & systems pharmacology.

Methodologies for Quantitative Systems Pharmacology (QSP) Models: Design and Estimation

B Ribba, HP Grimm, B Agoram, 2017, CPT: pharmacometrics & systems pharmacology.

A Review of Mixed-Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis

L E Friberg, N H Holford, P Magni, 2014, CPT: pharmacometrics & systems pharmacology.

Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth

B Ribba, Z. Kam, Y. Yarden, 2011, Oncogene.

The Use of Model‐Based Tumor‐Size Metrics to Predict Survival

N Holford, F Mentré, B Ribba, 2014, Clinical pharmacology and therapeutics.

Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias.

B Ribba, M Tod, B. Ribba, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings

B Ribba, M Tod, B. Ribba, 2015, CPT: pharmacometrics & systems pharmacology.

A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin’s lymphoma: Investigation of the current protocol through theoretical modelling results

P K Maini, B Ribba, P. Maini, 2005, Bulletin of mathematical biology.

A multiscale mathematical model of avascular tumor growth to investigate the therapeutic benefit of anti-invasive agents.

B Ribba, T Colin, D Bresch, 2006, Journal of theoretical biology.

Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice.

B Ribba, M Tod, Olivier Saut, 2013, Journal of theoretical biology.